1. Home
  2. CINGW vs BGB Comparison

CINGW vs BGB Comparison

Compare CINGW & BGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • BGB
  • Stock Information
  • Founded
  • CINGW N/A
  • BGB 2012
  • Country
  • CINGW United States
  • BGB United States
  • Employees
  • CINGW 13
  • BGB N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • BGB Trusts Except Educational Religious and Charitable
  • Sector
  • CINGW Health Care
  • BGB Finance
  • Exchange
  • CINGW Nasdaq
  • BGB Nasdaq
  • Market Cap
  • CINGW N/A
  • BGB N/A
  • IPO Year
  • CINGW 2021
  • BGB N/A
  • Fundamental
  • Price
  • CINGW $0.05
  • BGB $12.62
  • Analyst Decision
  • CINGW
  • BGB
  • Analyst Count
  • CINGW 0
  • BGB 0
  • Target Price
  • CINGW N/A
  • BGB N/A
  • AVG Volume (30 Days)
  • CINGW N/A
  • BGB 154.6K
  • Earning Date
  • CINGW N/A
  • BGB 01-01-0001
  • Dividend Yield
  • CINGW N/A
  • BGB 9.75%
  • EPS Growth
  • CINGW N/A
  • BGB N/A
  • EPS
  • CINGW N/A
  • BGB N/A
  • Revenue
  • CINGW N/A
  • BGB N/A
  • Revenue This Year
  • CINGW N/A
  • BGB N/A
  • Revenue Next Year
  • CINGW N/A
  • BGB N/A
  • P/E Ratio
  • CINGW N/A
  • BGB N/A
  • Revenue Growth
  • CINGW N/A
  • BGB N/A
  • 52 Week Low
  • CINGW N/A
  • BGB $10.40
  • 52 Week High
  • CINGW N/A
  • BGB $11.97
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • BGB 64.28
  • Support Level
  • CINGW N/A
  • BGB $12.29
  • Resistance Level
  • CINGW N/A
  • BGB $12.49
  • Average True Range (ATR)
  • CINGW 0.00
  • BGB 0.10
  • MACD
  • CINGW 0.00
  • BGB 0.03
  • Stochastic Oscillator
  • CINGW 0.00
  • BGB 92.68

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: